ArticleMolecular genetics and genomics : MGG2026
In vitro assessment of siRNA-mediated LRP5 silencing and temozolomide treatment in glioblastoma and brain cancer stem cells.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Research Progress on Anti-Inflammatory Adipokine SFRP5-Mediated Lipid Metabolism and Its Potential Role in Neural Development.Immunity, inflammation and disease · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Low-density lipoprotein receptor-related protein 5 (LRP5), a co-receptor of frizzled (FZD) in the WNT/β-catenin signaling pathway, recognizes Wnt ligands. This study aimed to assess the anti-cancer effects of silencing LRP5 on glioblastoma (GBM) and brain cancer stem cells (BCSCs). Additionally, the effect of temozolomide (TMZ) was also examined in these cells with suppressed LRP5 expression. LRP5 expression was silenced in U87MG, T98G, and BCSC cells using siRNA. Protein expression levels were determined by Western blotting. Cell viability after LRP5 silencing and/or TMZ treatment was evaluated using the CVDK-8 assay. Flow cytometry was used to examine apoptosis and cell cycle progression. Clonogenic, cell invasion, and wound-healing assays were used to assess colony formation, invasion, and migration, respectively. siRNA-mediated silencing reduced protein expression of LRP5 and Wnt/β-catenin target genes in GBM and BCSC cells. Furthermore, suppression of LRP5 reduced cell viability, and its combination with TMZ enhanced anti-proliferative effects. Silencing LRP5 and/or TMZ treatment caused cell cycle arrest and significantly diminished the aggressive characteristics of GBM and BCSC cells. These findings suggest that LRP5 may serve as a potential therapeutic target for treating GBM. Targeting LRP5 may enhance the effectiveness of the chemotherapy agent TMZ in GBM.
Indexed as
Identifiers
41619048What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.